Lord, Abbett & Co
JANX icon

Lord, Abbett & Co’s Janux Therapeutics JANX Stock Holding History

Lord, Abbett & Co’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-667,881
Closed -$18M – 551
2025
Q1 		$18M Sell
667,881
-599,922
-47% -$22.6M 0.06% 296
2024
Q4 		$67.9M Buy
1,267,803
+564,322
+80% +$29.8M 0.21% 129
2024
Q3 		$32M Buy
703,481
+874
+0.1% +$38K 0.1% 246
2024
Q2 		$29.4M Buy
702,607
+160,234
+30% +$7.52M 0.1% 251
2024
Q1 		$20.4M Buy
+542,373
New +$11.8M 0.07% 331

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return